Wilkerson Jenny L, Niphakis Micah J, Grim Travis W, Mustafa Mohammed A, Abdullah Rehab A, Poklis Justin L, Dewey William L, Akbarali Hamid, Banks Matthew L, Wise Laura E, Cravatt Benjamin F, Lichtman Aron H
Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, Virginia (J.L.W., T.W.G., M.A.M., R.A.A., J.L.P., W.L.D., H.A., M.L.B., L.E.W., A.H.L.); and The Skaggs Institute for Chemical Biology and Department of Chemical Physiology, The Scripps Research Institute, La Jolla, California (M.J.N., B.F.C.)
Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, Virginia (J.L.W., T.W.G., M.A.M., R.A.A., J.L.P., W.L.D., H.A., M.L.B., L.E.W., A.H.L.); and The Skaggs Institute for Chemical Biology and Department of Chemical Physiology, The Scripps Research Institute, La Jolla, California (M.J.N., B.F.C.).
J Pharmacol Exp Ther. 2016 Apr;357(1):145-56. doi: 10.1124/jpet.115.229971. Epub 2016 Jan 20.
Serious clinical liabilities associated with the prescription of opiates for pain control include constipation, respiratory depression, pruritus, tolerance, abuse, and addiction. A recognized strategy to circumvent these side effects is to combine opioids with other antinociceptive agents. The combination of opiates with the primary active constituent of cannabis (Δ(9)-tetrahydrocannabinol) produces enhanced antinociceptive actions, suggesting that cannabinoid receptor agonists can be opioid sparing. Here, we tested whether elevating the endogenous cannabinoid 2-arachidonoylglycerol through the inhibition of its primary hydrolytic enzyme monoacylglycerol lipase (MAGL), will produce opioid-sparing effects in the mouse chronic constriction injury (CCI) of the sciatic nerve model of neuropathic pain. The dose-response relationships of i.p. administration of morphine and the selective MAGL inhibitor 2,5-dioxopyrrolidin-1-yl 4-(bis(4-chlorophenyl)methyl)piperazine-1-carboxylate (MJN110) were tested alone and in combination at equieffective doses for reversal of CCI-induced mechanical allodynia and thermal hyperalgesia. The respective ED50 doses (95% confidence interval) of morphine and MJN110 were 2.4 (1.9-3.0) mg/kg and 0.43 (0.23-0.79) mg/kg. Isobolographic analysis of these drugs in combination revealed synergistic antiallodynic effects. Acute antinociceptive effects of the combination of morphine and MJN110 required μ-opioid, CB1, and CB2 receptors. This combination did not reduce gastric motility or produce subjective cannabimimetic effects in the drug discrimination assay. Importantly, combinations of MJN110 and morphine given repeatedly (i.e., twice a day for 6 days) continued to produce antiallodynic effects with no evidence of tolerance. Taken together, these findings suggest that MAGL inhibition produces opiate-sparing events with diminished tolerance, constipation, and cannabimimetic side effects.
用于控制疼痛的阿片类药物处方所带来的严重临床负担包括便秘、呼吸抑制、瘙痒、耐受性、滥用和成瘾。一种公认的规避这些副作用的策略是将阿片类药物与其他抗伤害感受药物联合使用。阿片类药物与大麻的主要活性成分(Δ⁹-四氢大麻酚)联合使用可增强抗伤害感受作用,这表明大麻素受体激动剂可以减少阿片类药物的用量。在此,我们测试了通过抑制内源性大麻素2-花生四烯酸甘油酯的主要水解酶单酰甘油脂肪酶(MAGL)来提高其水平,是否会在小鼠坐骨神经慢性压迫损伤(CCI)所致神经性疼痛模型中产生减少阿片类药物用量的效果。单独及以等效剂量联合腹腔注射吗啡和选择性MAGL抑制剂2,5-二氧代吡咯烷-1-基4-(双(4-氯苯基)甲基)哌嗪-1-羧酸酯(MJN110),测试其剂量-反应关系,以逆转CCI诱导的机械性异常性疼痛和热痛觉过敏。吗啡和MJN110各自的半数有效剂量(95%置信区间)分别为2.4(1.9-3.0)mg/kg和0.43(0.23-0.79)mg/kg。对这些联合使用药物的等效线图分析显示出协同抗异常性疼痛作用。吗啡和MJN110联合使用的急性抗伤害感受作用需要μ-阿片受体、CB1和CB2受体。在药物辨别试验中,这种联合用药并未降低胃动力或产生主观大麻样效应。重要的是,重复给予(即每天两次,共6天)MJN110和吗啡的联合用药持续产生抗异常性疼痛作用,且没有耐受性的证据。综上所述,这些发现表明抑制MAGL可产生减少阿片类药物用量的效果,同时耐受性、便秘和大麻样副作用也会减轻。